

FOI 2810

23rd December 2024**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Question One:

How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Question Two:

How many patients has your Trust treated in total in the past 3 months for

- Stage 2 Non Small Cell Lung Cancer
- Stage 3 Non Small Cell Lung Cancer

Question Three:

How many patients who received Pembrolizumab for Non Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received:

Pembrolizumab Monotherapy

1. Treatment every 3 weeks (200mg, Q3W)
2. Treatment every 6 weeks (400mg, Q6W)

Pembrolizumab in combination with chemotherapy

1. Treatment every 3 weeks (200mg, Q3W)
2. Treatment every 6 weeks (400mg, Q6W)

Response to Questions 1, 2, 3

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In

order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Email: Foi.Team@Southerntrust.hscni.net